Amgen Inc. (AMGN)
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen: Buy This Cheap Biotech Leader
Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised full-year guidance and is implying resilient bottom-line growth. The stock trades at a significant valuation discount to sector peers, making AMGN an attractive value play in the current environment.
Amgen Stock: New All-Time Highs Ahead After Earnings Beat
Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Amgen (AMGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates
Amgen (AMGN) came out with quarterly earnings of $5.64 per share, beating the Zacks Consensus Estimate of $5 per share. This compares to earnings of $5.58 per share a year ago.
